What Is Elicio Therapeutics, Inc. (ELTX) Worth in 2026?
According to the CirclFi Deep Alpha Valuation Engine, Elicio Therapeutics, Inc.'s intrinsic value is estimated at $4.49, suggesting a +47.7% average upside from the current price of $3.04. While 4 models see room for appreciation, model agreement is not unanimous as 3 models flag potential overvaluation. Model dispersion is worth noting: First Chicago targets $14.49 (+376.5%), versus Dynamic NAV at $0.61 (-79.9%). This +456.5% range highlights the importance of multi-model analysis rather than relying on any single methodology.
What Do the Models Say About ELTX?
7 of 13 models are currently active for ELTX. Of these, 4 models suggest upside while 3 models suggest overvaluation. The Bayesian DCF estimates ELTX's intrinsic value at $1.15, implying -62.0% downside from the current price. See which stocks rank higher →
How Does ELTX Rank in Pharmaceutical Preparations?
Among 431 Pharmaceutical Preparations stocks, ELTX ranks #352 by Quality of Company score. CirclFi's QOC score of 3.8/10 evaluates 32 fundamental signals. A score of 3.8 signals below-average fundamentals.
See all Most Undervalued Pharmaceutical Preparations Stocks →
As a biopharma enterprise, Elicio Therapeutics, Inc. operates in a sector where FDA approval probability is a critical driver of valuation. Investors evaluating ELTX should weigh these sector-specific dynamics alongside our model-derived fair values.
Is ELTX a Value Trap?
CirclFi's Value Trap algorithm assigns ELTX a score of 36/100 (LOW). This indicates low risk. The financial profile does not exhibit typical value trap warning signs. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →
Multi-Model Methodology
7 of 13 models are active for Elicio Therapeutics, Inc.. Moderate coverage provides meaningful perspective. Each model applies a fundamentally different valuation philosophy. See the complete methodology →
According to the CirclFi 32-factor quality framework, Elicio Therapeutics, Inc.'s fundamental quality profile registers 3.8/10. This mixed score captures the company's profitability depth, growth consistency, balance sheet resilience, and shareholder return track record.
The gap between the most bullish and bearish model spans +456.5% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →
Data Sources & Confidence
Every ELTX valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →
Across ELTX's 7 active models, average confidence is 22%. Lower confidence may reflect limited history or high volatility.
CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →
Buy with Gumroad